Barinthus Biotherapeutics (STU:2AB) Cash per Share: €1.40 (As of Mar. 2026)

What is Barinthus Biotherapeutics Cash per Share?

Barinthus Biotherapeutics STU:2AB 14 Cash per Share is €1.40 as of Mar. 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.94. The stock has 1 warning sign investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Barinthus Biotherapeutics's Cash per Share for the quarter that ended in Mar. 2026 was €1.40.

Barinthus Biotherapeutics (STU:2AB) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Barinthus Biotherapeutics Cash per Share Related Terms

Barinthus Biotherapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics Cash per Share Chart

Barinthus Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash per Share

Get a 7-Day Free Trial

5.09

4.87

3.37

2.63

1.47

Barinthus Biotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Cash per Share	Get a 7-Day Free Trial															2.27	1.85	1.55	1.47	1.40

14GF Score

Barinthus Biotherapeutics PLC STU:2AB

Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Barinthus Biotherapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Barinthus Biotherapeutics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	60.169	/	40.85
	=	1.47

Barinthus Biotherapeutics's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	56.967	/	40.85
	=	1.39

Frequently Asked Questions Learn more about Cash per Share →

What does a Cash per Share of €1.40 mean?

Barinthus Biotherapeutics (STU:2AB) has a Cash per Share of €1.40 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Barinthus Biotherapeutics and its competitors.

Is Barinthus Biotherapeutics' Cash per Share too high?

Barinthus Biotherapeutics' current Cash per Share is €1.40. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.

How does Barinthus Biotherapeutics' Cash per Share compare to VTGN and PSTV?

Barinthus Biotherapeutics' Cash per Share of €1.40 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash per Share for a Biotechnology company?

A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash per Share mean?

A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Cash per Share is €1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Barinthus Biotherapeutics stock overvalued right now?

Barinthus Biotherapeutics (STU:2AB) has a current Cash per Share of €1.40. The stock's GF Value™ is €0.94, compared to a current price of €0.52 — trading 44.7% below its estimated fair value. The current Cash per Share is €1.40. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash per Share calculated?

Cash per Share is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Cash per Share is €1.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.52 is trading 44.7% below its estimated GF Value™ of €0.94.

Key valuation signals for STU:2AB:

Cash per Share: €1.40
GF Value™: €0.94 vs. price of €0.52 (44.7% below fair value)
GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies VTGN PSTV PVCT KYNB TVGN GRDX DYAI NRSN SER LITS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges BRNS:USA

Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874

Website https://www.barinthusbio.com

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

14GF Score

Get the complete analysis for STU:2AB

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.52

Price

€0.94

GF Value

View STU:2AB Analysis

See Cash per Share data for all stocks →